Qihan Bio Unveils 2,500-Square-Meter GMP Facility for Cell and Gene Therapy in Hangzhou
Qihan Biotech
Gene Editing Technology Developer
Recently, the completion ceremony of Qihan Biotech's CGT (Cell and Gene Therapy) platform was held at the Jindi Xindao Lan Valley Life Science Park in Xiaoshan District, Hangzhou. Wang Xinlai, Standing Deputy Commander of Jiangnan Sci-Tech City Corps and Director of the Sci-Tech City Administration Bureau, Qian Guoen, Deputy Director of the District Science and Technology Bureau, Lou Taoyuan, and Huang Haijun, Deputy Directors of the Sci-Tech City Administration Bureau, attended the ceremony.
Hangzhou Qihan Biotech Co., Ltd. is a biotechnology company that applies high-throughput gene editing technology to the fields of cell therapy and organ transplantation, possessing globally leading innovative technology in the cell therapy sector. The newly constructed 2,500-square-meter GMP-level platform is designed in accordance with the regulatory requirements of the NMPA, FDA, and others, and can support the research, development, and production of cell and gene therapy products.
Lou Taoyuan pointed out in his speech that Qihan Biotech is an outstanding representative of scientific and technological innovation in Jiangnan Sci-Tech City. Over the past six years, Qihan Biotech has not only witnessed the development of Jiangnan Sci-Tech City but also led the city in continuously pioneering innovations in the biopharmaceutical field. Going forward, Jiangnan Sci-Tech City will continue to support the development of Qihan Biotech as always, and hopes that Qihan Biotech will prosper further and make greater contributions to the high-quality development of Jiangnan Sci-Tech City.
Yang Luhan, CEO of Hangzhou Qihan Biotech Co., Ltd., stated that the company will take the establishment of the platform as an opportunity to continuously improve its functionality, accelerate product iteration from research and development to production, and realize the vision of "creating a world where cell and organ therapies are accessible to every patient" as soon as possible.
E.N.D
Previous article recommendations:
CSPC's CAR-T Cell Therapy Approved for Clinical Trials, Targeting Systemic Lupus Erythematosus
Nearly $2 Billion! Roche Expands into Alzheimer's AAV Gene Therapy
First TCR-T Cell Therapy Launches at $727,000; Annual Sales Peak Could Reach $400 Million
35 Immunotherapy Companies and Pipelines Worth Watching
Northeast Pharmaceutical Plans to Acquire 70% Equity of a Cell Therapy Company
Over 1 billion yuan! Two Chinese companies reach commercial collaboration on CAR-T product
The World's First TCR-T Cell Therapy Approved for Marketing
Analysis of the Layout and Support Measures of the Biomedical Industry in Seven Typical Regions
World's First Base-Edited NK Cell Product Clinical Trial Application Accepted by CDE
iPSC/T/NK Cell Therapy CMC Production Process Solution
Langxin Bio's AAV Gene Therapy Drug LX101 Completes Enrollment for Phase III Clinical Trial
Hengrui Medicine Appoints Dr. Xuejian Xu as Vice President and Chief Quality Officer
The Commercialization Bottleneck of CAR-T Therapy is Not Just the "Sky-High Price"
Statement:The graphic content is sourced from the official Jiangnan Technology City. This article aims to share knowledge, and all content is for reference only and does not constitute any advice.